NASDAQ · Financial Statements
RedHill Biopharma Ltd. (RDHL) Financial Statements
$0.60
NASDAQ: RDHL
Market Cap $1.89M
Overview Financials Dividend
RedHill Biopharma Ltd. most recently reported annual revenue of $0, net profit of $0. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025
Revenue $86.0M $62.0M $7.0M $8.0M $0 Operating Profit $-81.0M $-43.0M $13.0M $-15.0M $-8.0M Net Profit $-98.0M $-72.0M $24.0M $-8.0M $0 EPS $-1000.00 $-600.00 $46.00 $-7.00 $0.00 Op Margin -94.6% -69.3% 193.4% -181.7% -2765.4%
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025
Total Assets $181.0M $159.0M $23.0M $18.0M $25.0M Total Liabilities $172.0M $207.0M $21.0M $23.0M $21.0M Cash $29.0M $20.0M $6.0M $5.0M $4.0M Borrowings $88.0M $123.0M $1.0M $0 $1.0M
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow $-65.0M $-29.0M $-36.0M $-9.0M $-10.0M Investing Cash Flow $-8.0M $8.0M $0 $0 $2.0M Financing Cash Flow $-3.0M $-11.0M $9.0M $1.0M $0 Net Cash Flow $0 $-10.0M $-14.0M $-1.0M $-1.0M Free Cash Flow $-65.0M $-29.0M $-36.0M $-9.0M $-10.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.00 EV / EBITDA 0.24 FCF Yield -266.20% Quick Ratio 0.34 Interest Coverage -4.28 Return 1Y -57.45% Return 3Y -97.14% Return 5Y —
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer .